As far as GSK3β inhibitors are concerned, LY2090314 is currently under investigation in a phase II trial of refractory/recurrent acute myeloid leukemia (clinicaltrials.gov identifier NCT01214603). This evidence concerns the gene GSK3B and acute myeloid leukemia.